Adagene Inc. (ADAG) News
Filter ADAG News Items
ADAG News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ADAG News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ADAG News From Around the Web
Below are the latest news stories about ADAGENE INC that investors may wish to consider to help them evaluate ADAG as an investment opportunity.
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?Here is how Adagene Inc. Sponsored ADR (ADAG) and Editas Medicine (EDIT) have performed compared to their sector so far this year. |
Is Bioventus (BVS) Outperforming Other Medical Stocks This Year?Here is how Bioventus (BVS) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year. |
Are Medical Stocks Lagging Adagene (ADAG) This Year?Here is how Adagene Inc. Sponsored ADR (ADAG) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year. |
November 2024's Top Picks: Penny Stocks On US ExchangesAs November 2024 comes to a close, the U.S. stock market has been making headlines with the S&P 500 and Dow Jones Industrial Average reaching record highs and posting their largest monthly gains of the year. Amidst this robust market performance, investors are increasingly exploring diverse opportunities, including those offered by penny stocks. While often considered a throwback to earlier trading days, penny stocks represent smaller or newer companies that can offer significant potential... |
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting- Improved safety and efficacy profiles for ADG126 versus ipilimumab driven by precision masking, novel epitope-dependent antibody-dependent cellular cytotoxicity (ADCC) and partial CTLA-4 blockade - - Clinical data show benefit of combining immune checkpoint inhibitors in MSS CRC and essential role of CTLA-4 to prime PD-L1 pathway - - Clinical poster selected by SITC as a ‘Top 100’ abstract out of 1439 regular abstracts - SAN DIEGO and SUZHOU, China, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adagene In |
Adagene And 2 Other US Penny Stocks To ConsiderAs the U.S. market experiences a mixed performance, with the S&P 500 and Dow Jones Industrial Average slipping from record highs while the Nasdaq continues to climb, investors are keenly observing opportunities in various sectors. Penny stocks, though an older term, remain relevant for those interested in smaller or newer companies that might offer significant growth potential. By focusing on penny stocks with strong financial health and a clear path forward, investors can uncover... |
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingSAN DIEGO and SUZHOU, China, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced poster presentations at the upcoming SITC 39th Annual Meeting, taking place in Houston, Nov. 6 – 10, 2024. Details include: Deciphering Improved Clinical Therapeutic Index (TI) of Muzastotug (ADG126), a Masked Anti-CTLA-4 SAFEbody® over its Unmasked Form (ADG116) as Monotherapy or in Combina |
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?Here is how DaVita HealthCare (DVA) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year. |
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)- Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for overall response rate (ORR) of 24% (4/17) with ADG126 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab - - Median progression-free survival of 8.5 months observed in patients without liver and peritoneal metastases at the ADG126 10 mg/kg Q3W dose - - At the 10 mg/kg dose level, 12-month overall survival (OS) rates were 74% for patients without liver |
Adagene to Participate in Investor Conferences in SeptemberSAN DIEGO and SUZHOU, China, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the company’s participation in several upcoming investor conferences in New York City. Management will host investor meetings and Adagene’s Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will present at the following ev |